MX342625B - Combinaciones antitumorales que contienen anticuerpos que reconocen específicamente cd38 y melfalan. - Google Patents

Combinaciones antitumorales que contienen anticuerpos que reconocen específicamente cd38 y melfalan.

Info

Publication number
MX342625B
MX342625B MX2011005670A MX2011005670A MX342625B MX 342625 B MX342625 B MX 342625B MX 2011005670 A MX2011005670 A MX 2011005670A MX 2011005670 A MX2011005670 A MX 2011005670A MX 342625 B MX342625 B MX 342625B
Authority
MX
Mexico
Prior art keywords
melfalan
antitumoral
specifically recognize
antibody
containing antibodies
Prior art date
Application number
MX2011005670A
Other languages
English (en)
Spanish (es)
Other versions
MX2011005670A (es
Inventor
Vrignaud Patricia
Lejeune Pascale
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40578382&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX342625(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MX2011005670A publication Critical patent/MX2011005670A/es
Publication of MX342625B publication Critical patent/MX342625B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2011005670A 2008-11-28 2009-11-27 Combinaciones antitumorales que contienen anticuerpos que reconocen específicamente cd38 y melfalan. MX342625B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08291116A EP2191840A1 (en) 2008-11-28 2008-11-28 Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
PCT/IB2009/055389 WO2010061357A1 (en) 2008-11-28 2009-11-27 Antitumor combinations containing antibodies recognizing specifically cd38 and melphalan

Publications (2)

Publication Number Publication Date
MX2011005670A MX2011005670A (es) 2011-09-30
MX342625B true MX342625B (es) 2016-10-06

Family

ID=40578382

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011005670A MX342625B (es) 2008-11-28 2009-11-27 Combinaciones antitumorales que contienen anticuerpos que reconocen específicamente cd38 y melfalan.

Country Status (33)

Country Link
US (1) US9259406B2 (enExample)
EP (2) EP2191840A1 (enExample)
JP (3) JP2012510461A (enExample)
KR (1) KR101733252B1 (enExample)
CN (1) CN102264385B (enExample)
AR (1) AR074219A1 (enExample)
AU (1) AU2009321249B2 (enExample)
BR (1) BRPI0921864B1 (enExample)
CA (1) CA2744990C (enExample)
CL (1) CL2011001254A1 (enExample)
CO (1) CO6440557A2 (enExample)
CR (1) CR20110280A (enExample)
EA (1) EA026867B1 (enExample)
EC (1) ECSP11011062A (enExample)
HN (1) HN2011001417A (enExample)
IL (1) IL213116B (enExample)
MA (1) MA32896B1 (enExample)
ME (1) ME01136B (enExample)
MX (1) MX342625B (enExample)
MY (1) MY164577A (enExample)
NI (1) NI201100105A (enExample)
NZ (1) NZ593027A (enExample)
PA (1) PA8850101A1 (enExample)
PE (1) PE20120340A1 (enExample)
PY (1) PY09043215A (enExample)
SG (1) SG171820A1 (enExample)
SV (1) SV2011003924A (enExample)
TN (1) TN2011000232A1 (enExample)
TW (1) TWI454260B (enExample)
UA (1) UA107069C2 (enExample)
UY (1) UY32263A (enExample)
WO (1) WO2010061357A1 (enExample)
ZA (1) ZA201103925B (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0816777B2 (ja) 1988-10-13 1996-02-21 富士写真フイルム株式会社 画像形成方法
EP2191840A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
EP2558571A4 (en) * 2010-04-16 2014-09-24 Immune Disease Inst Inc DELAYED POLYPEPTIDE EXPRESSION FROM MODIFIED SYNTHETIC RNAS AND USES THEREOF
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CN103118706B (zh) 2010-09-27 2016-05-18 莫佛塞斯公司 抗cd38抗体与来那度胺或硼替佐米用于治疗多发性骨髓瘤和nhl
DK4108671T3 (da) 2010-10-01 2025-01-06 Modernatx Inc Modificerede nukleosider, nukleotider og nukleinsyrer samt anvendelser deraf
UA112170C2 (uk) * 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
JP6113737B2 (ja) 2011-10-03 2017-04-12 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
EP2834259A4 (en) 2012-04-02 2016-08-24 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
BR112015006731A2 (pt) * 2012-09-25 2017-07-04 Morphosys Ag combinações e usos das mesmas
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
UA118255C2 (uk) * 2012-12-07 2018-12-26 Санофі Композиція, яка містить антитіло до cd38 і леналідомід
US10342869B2 (en) 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
US20150118251A1 (en) 2013-10-31 2015-04-30 Sanofi Specific anti-cd38 antibodies for treating human cancers
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US10617757B2 (en) 2014-08-08 2020-04-14 The Regents Of The University Of California Methods for treating multiple myeloma
EP3191187B1 (en) 2014-09-09 2021-07-28 Janssen Biotech, Inc. Combination therapies with anti-cd38 antibodies
JP6802791B2 (ja) 2014-12-04 2020-12-23 ヤンセン バイオテツク，インコーポレーテツド 急性骨髄性白血病の治療のための抗ｃｄ３８抗体
BR112017024877A2 (pt) 2015-05-20 2019-09-17 Janssen Biotech, Inc. anticorpo anti-cd38 e seu uso no tratamento de amiloidose de cadeia leve e outras malignidades hematológicas positivas para cd38
NZ777133A (en) 2015-06-22 2025-05-02 Janssen Biotech Inc Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
MD3827845T2 (ro) 2015-11-03 2022-09-30 Janssen Biotech Inc Formulări subcutanate de anticorpi anti-CD38 și utilizări ale acestora
US20190233533A1 (en) 2016-06-28 2019-08-01 Umc Utrecht Holding B.V. Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38
EP3484923A1 (en) 2016-07-15 2019-05-22 Takeda Pharmaceutical Company Limited Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
MA50514A (fr) 2017-10-31 2020-09-09 Janssen Biotech Inc Méthodes de traitement du myélome multiple à haut risque
US20210145778A1 (en) * 2018-01-01 2021-05-20 Orbicular Pharmaceutical Technologies Pvt. Ltd. Stable Liquid Compositions of Melphalan
CN112739715A (zh) 2018-01-12 2021-04-30 武田药品工业株式会社 抗cd38抗体的皮下给药
US12274733B2 (en) 2018-09-28 2025-04-15 President And Fellows Of Harvard College Cellular reprogramming to reverse aging and promote organ and tissue regeneration
CN113453702A (zh) 2018-09-28 2021-09-28 哈佛大学的校长及成员们 细胞重编程以逆转衰老并促进组织和组织再生
JP7687956B2 (ja) 2019-03-15 2025-06-03 モルフォシス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 自己抗体介在性自己免疫疾患の処置のための、抗ｃｄ３８抗体及びその医薬組成物
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
TW202133879A (zh) 2019-12-05 2021-09-16 美商賽諾菲阿凡提斯美國有限責任公司 用於皮下投予之抗cd38抗體的調配物
TW202235435A (zh) 2021-01-14 2022-09-16 德商莫菲西斯公司 抗cd38抗體及其用途
TW202302642A (zh) 2021-03-01 2023-01-16 德商莫菲西斯公司 用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體
TW202321303A (zh) 2021-07-19 2023-06-01 德商莫菲西斯公司 抗pla2r自體抗體媒介膜性腎病變之治療
US12252518B2 (en) 2023-01-06 2025-03-18 Life Biosciences, Inc. Methods of treating non-arteritic anterior ischemic optic neuropathy

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB750155A (en) 1953-03-17 1956-06-13 Nat Res Dev Substituted alanines
US3032585A (en) 1954-12-03 1962-05-01 Nat Res Dev Process for the production of p-bis-(2-chloroethyl)-aminophenylalanine
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
ES2087997T3 (es) 1990-01-12 1996-08-01 Cell Genesys Inc Generacion de anticuerpos xenogenicos.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
SI0970126T1 (en) 1997-04-14 2001-08-31 Micromet Ag Novel method for the production of antihuman antigen receptors and uses thereof
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
AU770718B2 (en) * 1998-06-05 2004-02-26 Mayo Foundation For Medical Education And Research Use of genetically engineered antibodies to CD38 to treat multiple myeloma
US7223397B1 (en) 1999-01-07 2007-05-29 Research Development Foundation Potentiation of anti-CD38-Immunotoxin cytotoxicity
GB0221574D0 (en) 2002-09-17 2002-10-23 Isis Innovation Treatments
NZ548990A (en) 2004-02-06 2009-06-26 Morphosys Ag Anti-CD38 human antibodies and uses therefor
EP3312196B1 (en) * 2005-03-23 2019-07-17 Genmab A/S Antibodies against cd38 for treatment of multiple myeloma
NZ576122A (en) 2006-09-26 2012-09-28 Genmab As Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors
US20080092384A1 (en) * 2006-10-16 2008-04-24 Schaake Mark D Installation of Middle Bearing for a Crankshaft
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EP2191841A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
EP2191843A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
EP2191840A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan

Also Published As

Publication number Publication date
PE20120340A1 (es) 2012-04-17
JP2017141233A (ja) 2017-08-17
HK1164165A1 (en) 2012-09-21
AU2009321249A1 (en) 2010-06-03
IL213116A0 (en) 2011-07-31
UA107069C2 (uk) 2014-11-25
BRPI0921864B1 (pt) 2022-11-16
KR101733252B1 (ko) 2017-05-08
EA026867B1 (ru) 2017-05-31
TW201023855A (en) 2010-07-01
IL213116B (en) 2018-11-29
US9259406B2 (en) 2016-02-16
CA2744990C (en) 2019-05-07
SV2011003924A (es) 2011-10-07
EA201100864A1 (ru) 2011-12-30
BRPI0921864A2 (en) 2018-10-09
HN2011001417A (es) 2014-01-13
TN2011000232A1 (en) 2012-12-17
UY32263A (es) 2010-06-30
WO2010061357A1 (en) 2010-06-03
CR20110280A (es) 2011-09-20
JP6148696B2 (ja) 2017-06-14
AR074219A1 (es) 2010-12-29
KR20110096550A (ko) 2011-08-30
EP2191840A1 (en) 2010-06-02
ZA201103925B (en) 2012-09-26
CN102264385B (zh) 2015-05-20
SG171820A1 (en) 2011-07-28
US20110274686A1 (en) 2011-11-10
MX2011005670A (es) 2011-09-30
JP2012510461A (ja) 2012-05-10
ME01136B (me) 2013-03-20
ECSP11011062A (es) 2011-07-29
MA32896B1 (fr) 2011-12-01
CO6440557A2 (es) 2012-05-15
NZ593027A (en) 2012-12-21
PA8850101A1 (es) 2010-07-27
TWI454260B (zh) 2014-10-01
CL2011001254A1 (es) 2012-01-27
AU2009321249B2 (en) 2016-06-09
MY164577A (en) 2018-01-15
CA2744990A1 (en) 2010-06-03
EP2370094A1 (en) 2011-10-05
NI201100105A (es) 2011-12-13
CN102264385A (zh) 2011-11-30
PY09043215A (es) 2013-11-01
JP2015205890A (ja) 2015-11-19

Similar Documents

Publication Publication Date Title
MX342625B (es) Combinaciones antitumorales que contienen anticuerpos que reconocen específicamente cd38 y melfalan.
MX344973B (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente la cd38 y la citarabina.
ES2675847T3 (es) Nuevo anticuerpo anti-DR5
MX337873B (es) Conjugados de anticuerpo farmaco (adc) que enlazan a proteinas 191p4d12.
AR122771A2 (es) Anticuerpos para el tratamiento del cáncer, conjugado, composición farmacéutica, ácido nucleico y célula huésped
CO6331346A2 (es) Anticuerpos anti-factor d humanizados, secuencias, composiciones, kit y articulo de fabricacion del mismo
AR083747A1 (es) Anticuerpos anti-il-23
AR117911A2 (es) Anticuerpo anti-158p1d7 o fragmento de unión a antígeno del mismo, conjugado fármaco-anticuerpo, composición farmacéutica y sus usos
UY30776A1 (es) Anticuerpos cd44
MX354101B (es) FORMULACION PARA ANTICUERPO ANTI -A4ß7.
CY1119647T1 (el) Αντισωματα προσδεσης αλβουμινης και τμηματα προσδεσης αυτων
EA201491569A1 (ru) МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С СИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ
AR109355A2 (es) Moléculas de unión al receptor ox40 humano
ES2670621T3 (es) Anticuerpos que se unen a OX40 y sus usos
EA201100869A1 (ru) Противоопухолевые комбинации, содержащие специфически распознающие cd38 антитела и циклофосфамид
PE20140004A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y bortezomib
CO6700829A2 (es) Moduladores novedosos y métodos de uso
EA201101593A1 (ru) КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА
PE20120306A1 (es) Anticuerpos anti-egfr y vectores que los codifican
PE20110821A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y vincristina
EA201490677A1 (ru) Связывающие антиген cd27l белки
UA113728C2 (xx) Фармацевтична композиція, яка містить антитіло до pcsk9 людини
CO6251325A2 (es) Un anticuerpo humano o humanizado, o un fragmento del mismo con una region de enlace de antigeno que es especifica para dirigir la proteina al receptor de limfoproteina estromal timica humana (htslpr)
CO6430469A2 (es) Anticuerpos humanizados que se unen a cd19 y sus usos
AR059432A1 (es) Anticuerpos anti-fgf19 y metodos que usan estos

Legal Events

Date Code Title Description
FG Grant or registration